Perkutane bildgeführte Radiofrequenzablation von Nierentumoren

Sommer, Christof M.; Kauczor, Hans Ulrich; Pereira, P. L.

doi:10.1007/s00120-014-3672-4

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advantages of radiofrequency ablation include the rare occurrence of deterioration of renal function with an overall 5-year survival rate of 58-85%, according to meta-analyses (4). Radiofrequency ablation is indicated in T1 tumours (i.e.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Analgesic effects of dexmedetomidine and remifentanil on periprocedural pain during percutaneous ablation of renal carcinoma

Semenas

Lönnemark

Dahlman

et al. 2020

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

Background: Percutaneous ablation of renal carcinoma is frequently a favourable treatment alternative, especially in elderly patients suffering from co-morbidities. Also, it is less resource-demanding than conventional surgery of renal carcinoma, and one may, therefore, assume that the incidence of this procedure may increase. Analgesia is necessary during this intervention. The aim of this study was to explore the possibility of analgosedation and its relation to patient comfort and safety during percutaneous ablation of renal carcinoma. Methods: Forty-six patients, sedated with dexmedetomidine and remifentanil, supplemented with infiltration anaesthesia (lidocaine 1%), underwent percutaneous (radiofrequency or microwave) ablation of renal carcinoma in this prospective study. Results: The patients expected pain intensity around the numerical rating score (NRS) 4.5 (interquartile range [IQR] 3.5-5.5), which was slightly lower than pain experienced during the procedure NRS 5 (IQR 2-7; p ¼ 0.49). Eight percent of the patients needed supplementary morphine during the ablation procedure. Sedation score did not differ during ablation, at arrival to or discharge from the recovery ward. Median periprocedural treatment time was 12 minutes (IQR 12-16). Treatment time did not correlate with experienced pain (R 2 ¼0.000074, p ¼ 0.96). The median length of stay in the recovery room was 120 minutes (IQR 84-154). There were seven serious adverse events. Conclusions: This proof-of-concept study has shown that analgosedation during percutaneous ablation of renal carcinoma can be performed with a generally tolerable degree of patient satisfaction. However, pain occurs and should be managed adequately. Patient safety must be a major concern for the anaesthetic care.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Major complication rates (e.g. relevant deterioration of renal function) are reported in 0-14% of interventions (4).…”

Section: Introductionmentioning

confidence: 99%

Analgesic effects of dexmedetomidine and remifentanil on periprocedural pain during percutaneous ablation of renal carcinoma

Semenas

Lönnemark

Dahlman

et al. 2020

Upsala Journal of Medical Sciences

View full text Add to dashboard Cite

show abstract

Was kann/soll bei Nierentumoren wann behandelt werden

et al. 2017

View full text Add to dashboard Cite

Apart from localized renal cell carcinoma, angiomyolipoma and oncocytoma can be treated by thermal ablation. Transarterial embolization extends the radiological spectrum for the treatment of renal tumors, either as complementary embolization (e. g. before thermal ablation of T1a and T1b renal cell carcinoma), prophylactic embolization (e. g. angiomyolipoma >6 cm), preoperative embolization (e. g. before laparoscopic partial nephrectomy) or palliative embolization (e. g. in patients with symptomatic macrohematuria due to renal cell carcinoma).

show abstract